-The "Computer-Aided Drug Discovery Services Market, 2018-2030" report has been added to ResearchAndMarkets.com `s offering. The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical an
Valley Cottage, NY 08/14/2018 Future Market Insights presents pertinent insights and a revised forecast of the global 3 D printed medical devices market in its published report titled' 3 D Printed Medical Devices Market ": Global Industry Analysis and Opportunity Assessment'. The global 3 D printed medical devices market is expected to expand
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D Alvise, p
The American College of Radiology issued the following news release:. The American College of Radiology Liver Imaging Reporting and Data System steering committee developed and approved a new version of CT/MRI LI-RADS, thus reaching a critical milestone of integration into the American Association for the Study of Liver Diseases 2018 hepatocellular
Actinium Pharmaceuticals, Inc., today announced that it will conduct a conference call on Wednesday, August 15, 2018 at 9:00 AM ET to provide an update on the Pivotal Phase 3 SIERRA Trial of Iomab-B. Date: Wednesday, August 15, 2018 Time: 9:00 AM ET Registration Link: https://onecast.thinkpragmatic.com/ses/HKwlrC68IHB-UiNbwrpb4w~~ Toll-Free Dial-
But experts who pay close attention to federal drug policy and Medicare rules say the administration is preparing to incrementally roll out a multipronged plan that tasks the Centers for Medicare& Medicaid Services and the Food and Drug Administration with promoting competition, attacking the complicated drug rebate system and introducing tactics t
-Adherium, a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie solution in the U.S., following its recent Food and Drug Administration 510 over-the-counter clearance to enable sales direct to consumers. Adherium believes health technology should be simple to use
Aevi Genomic Medicine, Inc. today announced that it has completed enrollment in Part A of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder, to confirm response to AEVI-001 in these patients. "We are pleased that we hav
This is a significant victory for Alnylam, and for biotech in general, which has been struggling for more than a decade to transform RNAi technology into an approval medicine. Alnylam has beaten off competition in the US from RNAi company Ionis, which is developing a rival therapy for hATTR, Tegsedi. But Alnylam is ahead in the bigger US market, wh
Amicus Therapeutics Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease. Galafold was approved using the Accelerated Approval pathway, which allows the US Food and Drug Administration to approve drugs for serious conditions where there is an unmet medical need if a treatment drug is shown
Amicus Therapeutics first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy. The oral drug is an alternative to the infused enzyme replacement therapy that is current standard of care Sanofi/ Genzymes Fabarazyme. Already approved in Europe,
The battle between Vertex Pharmaceuticals and U.K. health officials over cystic fibrosis drug pricing has reached an impasse after NHS Englands final offer in July. In a statement, Vertex director of external communications Heather Nichols said the company supports the need for robust and fair medicines appraisal in England. Vertex and U.K. health.
BAUDETTE- ANI Pharmaceuticals, Inc. ANIP, -1.74% today reported its financial results for the three and six months ended June 30, 2018 and updated its 2018 financial guidance. Arthur S. Przybyl, President and CEO, stated,' In the second quarter of 2018 ANI continued to successfully execute on its strategy to grow the brand and generic business plat
Non-profit research organisation Population Council has secured the US Food and Drug Administration approval for a new contraceptive vaginal ring called Annovera. Population Council president Julia Bunting said: Nearly half of all pregnancies in the US are unintended, which can increase health risks for mom and baby. During the Phase III programme,
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that the Company`s lipid nanoparticle licensee, Alnylam Pharmaceuticals, Inc., announced that their new drug application for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration for the treatment o
Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties including, but not limited to the factors set forth under the heading "Forward Looking Statements" and "Item 1 A. Risk Factors" under Part I of this Annual Report on Form 10- K, and in other reports we file with the SEC. Ther
Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs. "We were thrilled to launch BRAFTOVI?+ MEKTOVI for patients with BRAF- mutant melanoma in the U.S. after receiving FDA approval for the combi
Arrayit Corporation, a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens.
PASADENA- Arrowhead Pharmaceuticals Inc. today announced financial results for its fiscal 2018 third quarter ended June 30, 2018. Made presentations at the EASL International Liver Congress, including: Preclinical data on ARO-AAT, the second generation candidate for the treatment of alpha-1 antitrypsin deficiency liver disease, Preclinical data on.
AVEO Oncology today announced that the China National Drug Administration has accepted CANbridge Life Sciences Investigational New Drug Application for a Phase Ib/III clinical trial of CAN017, AVEO s clinical-stage ErbB3 inhibitory antibody candidate, in esophageal squamous cell cancer. Under the terms of a March 2016 agreement, the acceptanc
On August 14, 2018, AVEO Pharmaceuticals, Inc. issued a press release announcing that the China National Drug Administration has accepted an investigational new drug application of CANbridge Life Sciences for a Phase 1 b/III clinical trial of CAN017 in esophageal squamous cell cancer. CAN017, which the Company refers to as AV-203, is the Company's.
The U.S. health insurance industry's premium composition is increasingly shifting toward government-sponsored business, which exposes carriers to additional risks as the business is generally low-margin and results in a greater reliance on state and federal funding, according to a new A.M. Best report. Medicaid reported the largest increase in net.
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the quarter ended June 30, 2018, and provided a review of recent accomplishments and anticipated...
In 2017, 12 biologics were approved in the USA, 10 in European Union and 7 in Japan. North America had the highest share in 2017 at $39.2 billion followed by Western Europe with a market value of $26.4 billion. Of these, humanized mAbs accounted for 43% share in the monoclonal antibody market with a market value of $37.6 billion followed by human m